Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Follow-up of CRISPR CAR Cellular Therapies in Malignancies
2024-512479-11-00Phase 2Authorised
- Sponsor
- CRISPR Therapeutics
- Start
- May 2024
- Modality
- CRISPR-Cas9 → CRISPR Systems → Programmable Nucleases → Gene Editing → Gene Therapies, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of allogeneic CRISPR/Cas9-edited anti-CD19 CAR T cells in Non-hematologic malignancy and hematopoietic malignancies, sponsored by CRISPR Therapeutics. Primary endpoint: Incidence of adverse events including serious adverse events and adverse events of special interest. Planned start May 2024; status: authorised.
02
Drugs
allogeneic CRISPR/Cas9-edited anti-CD19 CAR T cells
03
Conditions
Non-hematologic malignancyhematopoietic malignancies
Beyond the preview
Go deeper on 2024-512479-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512479-11-00.